The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment
Open accessAbstract
Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of illicit fentanyl is a recent phenomenon. Starting in 2013, illicitly manufactured fentanyl and its analogs began to appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl, and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit fentanyl use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J., & Caron, M. G. (2000) · Nature · doi:10.1038/35047086 · Cited by 927
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 4×
“Note, the reduced abuse potential with prior pain to opioid exposure may not apply to individuals with comorbidities of posttraumatic stress disorder, depression and anxiety or the presence of catastrophizing (Evans & Cahill, 2016). by GTPγS binding in cells expressing mouse or human MORs (Schmid et al., 2017).”
BackgroundInfluentialFishbain, D. A., Cole, B., Lewis, J., Rosomoff, H. L., & Rosomoff, R. S. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00370.x · Cited by 565
Traynor, J. R., & Nahorski, S. R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08634-1 · Cited by 462
Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004
Cicero, T. J., Inciardi, J. A., & Muñoz, A. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2005.05.004 · Cited by 461
Cited by
Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies
Maffei, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217877 · Cited by 150
The epidemic of fentanyl misuse and overdoses: challenges and strategies
Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20846 · Cited by 89
Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated
Varshneya, N. B., Hassanien, S. H., Holt, M. C., Stevens, D. L., Layle, N. K., Bassman, J. R., Iula, D. M., & Beardsley, P. M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114805 · Cited by 62
New Synthetic Opioids: Clinical Considerations and Dangers
Edinoff, A. N., Martinez Garza, D., Vining, S. P., Vasterling, M. E., Jackson, E. D., Murnane, K. S., Kaye, A. M., Fair, R. N., Torres, Y. J. L., Badr, A. E., et al. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00481-6 · Cited by 61
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
Metadata
- Authors
- Comer, S. D., & Cahill, C. M.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 106
- Pages
- 49-57
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2903520456
- Cited by
- 302
- References
- 90
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. https://app.cochat.ai/papers/10.1016/j.neubiorev.2018.12.005
- The paper
- Comer, S. D., & Cahill, C. M. (2019). Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2018.12.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.